Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $420.1 million.

  • Arrowhead Pharmaceuticals' Other Gross PP&E Adjustments rose 444.85% to $420.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $420.1 million, marking a year-over-year increase of 444.85%. This contributed to the annual value of $408.3 million for FY2025, which is 529.89% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Other Gross PP&E Adjustments of $420.1 million as of Q4 2025, which was up 444.85% from $408.3 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Gross PP&E Adjustments ranged from a high of $420.1 million in Q4 2025 and a low of $7.0 million during Q2 2022
  • Its 5-year average for Other Gross PP&E Adjustments is $196.6 million, with a median of $81.1 million in 2023.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Other Gross PP&E Adjustments crashed by 7132.88% in 2022, and later soared by 64573.3% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at $28.9 million in 2021, then soared by 62.15% to $46.8 million in 2022, then surged by 607.18% to $331.3 million in 2023, then grew by 21.4% to $402.2 million in 2024, then increased by 4.45% to $420.1 million in 2025.
  • Its Other Gross PP&E Adjustments stands at $420.1 million for Q4 2025, versus $408.3 million for Q3 2025 and $410.9 million for Q2 2025.